Next Score View the next score

    Novartis, Amgen join venture fund

    The biopharmaceutical companies Novartis AG and Amgen Inc. have signed on as limited partners in a new $265 million venture capital fund raised by the Cambridge firm Atlas Venture.

    The new fund, Atlas Venture Fund IX, will invest in biomedical and life sciences start-ups.

    Separately, Novartis, a Swiss company that runs its global research operations from Cambridge, and California-based Amgen, which also has a research center in ­Cambridge, have entered into corporate strategic partnerships with Atlas Venture, the partners said.


    The alliances will “provide Amgen and Novartis with strategic proximity to Atlas Venture’s start-up formation activities around innovative, potentially high impact medicines, and catalyze future collaborations around translational research,” the venture firm said in a statement.

    Robert Weisman

    Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.